Lannett Acquires Portfolio Of Generic Products From Endo International

Transaction Includes 23 Approved and 1 Pending Drug Product Applications, Primarily Oral Solutions PHILADELPHIA, May 7, 2018 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it has acquired 23 approved... Biopharmaceuticals, Generic, Acquisitions Lannett Company, Endo International
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news